LONDON, April 27 (Reuters) - AstraZeneca on Thursday beat expectations for its first -quarter profit and revenue, helped by sales of some of its oncology as well as rare blood disorder drugs.
The London-listed drugmaker, which reports its results in U.S. dollars, reported adjusted profit of $1.92 per share on sales of about $10.9 billion.
Analysts on average were expecting $1.71 per share on sales of about $10.6 billion, according to company-compiled consensus estimates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments